![](https://bostonglobe-prod.cdn.arcpublishing.com/resizer/Fyx9WBbaUKrb2hTl2sWLi-IOLTY=/506x0/cloudfront-us-east-1.images.arcpublishing.com/bostonglobe/P225HDVYOZYH62DBQEAOV7JYZ4.jpg)
Alnylam shares surge as biotech trumpets positive trial results of heart disease drug
Alnylam Pharmaceuticals said Monday that a drug to treat a rare genetic heart disorder met all its goals in a late-stage clinical trial, raising the prospect that the medicine could generate billions of dollars for the Cambridge biotech. Shares of Alnylam …